drugset / Trial / NCT02296541

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

NCT02296541

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immune response to three DNA vaccines and a MVA-CMDR vaccine that may boost the immune response to the DNA vaccines in healthy, HIV-uninfected adults.

Timeline

Start
2014-12
Primary completion
2016-11
Completion
2020-07-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DNA CON-S env Vaccine 4 mg Intramuscular
Subject DNA Mosaic env Vaccine 4 mg Intramuscular
Subject DNA Nat-B env Vaccine 4 mg Intramuscular
Subject MVA-CMDR Vaccine 1e+08 unknown Intramuscular